1-(3-chlorophenyl)piperazine has been researched along with Anankastic Personality in 41 studies
1-(3-chlorophenyl)piperazine: supposed metabolite of TRAZODONE; RN given refers to parent cpd; structure
1-(3-chlorophenyl)piperazine : A N-arylpiperazine that is piperazine carrying a 3-chlorophenyl substituent at position 1. It is a metabolite of the antidepressant drug trazodone.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the effect of fluoxetine on serotonergic sensitivity in obsessive-compulsive disorder (OCD), the partial serotonin agonist metachlorophenylpiperazine (mCPP) was compared to placebo under double-blind conditions in six patients with OCD before and during treatment with fluoxetine." | 9.07 | Effects of chronic fluoxetine treatment on behavioral and neuroendocrine responses to meta-chlorophenylpiperazine in obsessive-compulsive disorder. ( DeCaria, C; Gorman, JM; Gully, R; Hollander, E; Klein, DF; Liebowitz, MR; Nitescu, A; Suckow, RF, 1991) |
| "Clomipramine is a potent serotonin reuptake blocker that decreases the symptoms of obsessive-compulsive disorder (OCD)." | 9.06 | Serotonergic responsivity in obsessive-compulsive disorder. Effects of chronic clomipramine treatment. ( Hill, JL; Insel, TR; Murphy, DL; Zohar, J; Zohar-Kadouch, RC, 1988) |
| "To evaluate the role of serotonin (5-HT) function in obsessive-compulsive disorder (OCD), behavioral and biochemical responses to the 5-HT receptor agonist m-chlorophenylpiperazine (MCPP) and the 5-HT precursor tryptophan were examined in healthy subjects and patients with OCD." | 7.67 | Serotonin function in obsessive-compulsive disorder. A comparison of the effects of tryptophan and m-chlorophenylpiperazine in patients and healthy subjects. ( Charney, DS; Goodman, WK; Heninger, GR; Price, LH; Rasmussen, SA; Woods, SW, 1988) |
| "Pretreatment with ondansetron did not affect any of the self-rated behavioral symptoms." | 6.69 | Acute intravenous administration of ondansetron and m-CPP, alone and in combination, in patients with obsessive-compulsive disorder (OCD): behavioral and biological results. ( Broocks, A; Canter, S; Grady, TA; Hill, JL; L'Heureux, F; Murphy, DL; Pigott, TA, 1998) |
| " The doses of modulators were selected on the basis of dose-response studies." | 5.39 | Effects of agomelatine in a murine model of obsessive-compulsive disorder: interaction with meta-chlorophenylpiperazine, bicuculline, and diazepam. ( Bhutada, P; Deshmukh, P; Dixit, P; Kaulaskar, S; Thakur, K, 2013) |
| "To investigate the effect of fluoxetine on serotonergic sensitivity in obsessive-compulsive disorder (OCD), the partial serotonin agonist metachlorophenylpiperazine (mCPP) was compared to placebo under double-blind conditions in six patients with OCD before and during treatment with fluoxetine." | 5.07 | Effects of chronic fluoxetine treatment on behavioral and neuroendocrine responses to meta-chlorophenylpiperazine in obsessive-compulsive disorder. ( DeCaria, C; Gorman, JM; Gully, R; Hollander, E; Klein, DF; Liebowitz, MR; Nitescu, A; Suckow, RF, 1991) |
| "Clomipramine is a potent serotonin reuptake blocker that decreases the symptoms of obsessive-compulsive disorder (OCD)." | 5.06 | Serotonergic responsivity in obsessive-compulsive disorder. Effects of chronic clomipramine treatment. ( Hill, JL; Insel, TR; Murphy, DL; Zohar, J; Zohar-Kadouch, RC, 1988) |
| "We have proposed rewarded T-maze alternation as a model of obsessive-compulsive disorder (OCD): the serotonin agonist m-chlorophenylpiperazine (mCPP) increments persistence therein, while chronic pretreatment with selective serotonin reuptake inhibitor (SSRI fluoxetine) but not benzodiazepine or desipramine abolishes mCPP effects." | 3.74 | Dopaminergic and serotonergic modulation of persistent behaviour in the reinforced spatial alternation model of obsessive-compulsive disorder. ( Boulougouris, V; Kalogerakou, S; Kontis, D; Papadimitriou, GN; Papadopoulos, S; Papakosta, VM; Poulopoulou, C; Tsaltas, E, 2008) |
| "To evaluate the role of serotonin (5-HT) function in obsessive-compulsive disorder (OCD), behavioral and biochemical responses to the 5-HT receptor agonist m-chlorophenylpiperazine (MCPP) and the 5-HT precursor tryptophan were examined in healthy subjects and patients with OCD." | 3.67 | Serotonin function in obsessive-compulsive disorder. A comparison of the effects of tryptophan and m-chlorophenylpiperazine in patients and healthy subjects. ( Charney, DS; Goodman, WK; Heninger, GR; Price, LH; Rasmussen, SA; Woods, SW, 1988) |
| " Each subject was tested two times, receiving both times the same dosage of mCPP or placebo with ritanserin or placebo pre-treatment." | 2.73 | Hypersensitivity of 5-HT2 receptors in OCD patients. An increased prolactin response after a challenge with meta-chlorophenylpiperazine and pre-treatment with ritanserin and placebo. ( de Leeuw, AS; Westenberg, HG, 2008) |
| "Pretreatment with ondansetron did not affect any of the self-rated behavioral symptoms." | 2.69 | Acute intravenous administration of ondansetron and m-CPP, alone and in combination, in patients with obsessive-compulsive disorder (OCD): behavioral and biological results. ( Broocks, A; Canter, S; Grady, TA; Hill, JL; L'Heureux, F; Murphy, DL; Pigott, TA, 1998) |
| " The doses of modulators were selected on the basis of dose-response studies." | 1.39 | Effects of agomelatine in a murine model of obsessive-compulsive disorder: interaction with meta-chlorophenylpiperazine, bicuculline, and diazepam. ( Bhutada, P; Deshmukh, P; Dixit, P; Kaulaskar, S; Thakur, K, 2013) |
| "desipramine) treatment (both 10 mg/kg; 20 mg/kg x 21 days)." | 1.35 | Stereotypic behaviour in the deer mouse: pharmacological validation and relevance for obsessive compulsive disorder. ( Harvey, BH; Korff, S; Stein, DJ, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (14.63) | 18.7374 |
| 1990's | 20 (48.78) | 18.2507 |
| 2000's | 8 (19.51) | 29.6817 |
| 2010's | 6 (14.63) | 24.3611 |
| 2020's | 1 (2.44) | 2.80 |
| Authors | Studies |
|---|---|
| da Silva, JF | 1 |
| Taguchi, LM | 1 |
| Leite, EDS | 1 |
| de Oliveira, AR | 2 |
| Reimer, AE | 1 |
| Diniz, JB | 1 |
| Hoexter, MQ | 1 |
| Miguel, EC | 1 |
| Milad, MR | 1 |
| Brandão, ML | 1 |
| Bhutada, P | 1 |
| Dixit, P | 1 |
| Thakur, K | 1 |
| Deshmukh, P | 1 |
| Kaulaskar, S | 1 |
| Tucci, MC | 3 |
| Dvorkin-Gheva, A | 3 |
| Sharma, R | 1 |
| Taji, L | 2 |
| Cheon, P | 2 |
| Peel, J | 2 |
| Kirk, A | 2 |
| Szechtman, H | 3 |
| Johnson, E | 1 |
| Wong, M | 1 |
| de Leeuw, AS | 1 |
| Westenberg, HG | 2 |
| Kontis, D | 2 |
| Boulougouris, V | 1 |
| Papakosta, VM | 1 |
| Kalogerakou, S | 1 |
| Papadopoulos, S | 1 |
| Poulopoulou, C | 1 |
| Papadimitriou, GN | 1 |
| Tsaltas, E | 2 |
| Kreiss, DS | 1 |
| Coffman, CF | 1 |
| Fiacco, NR | 1 |
| Granger, JC | 1 |
| Helton, BM | 1 |
| Jackson, JC | 1 |
| Kim, LV | 1 |
| Mistry, RS | 1 |
| Mizer, TM | 1 |
| Palmer, LV | 1 |
| Vacca, JA | 1 |
| Winkler, SS | 1 |
| Zimmer, BA | 1 |
| Graham, D | 1 |
| Amodeo, S | 1 |
| Gross-Isseroff, R | 1 |
| Cohen, R | 1 |
| Sasson, Y | 1 |
| Voet, H | 1 |
| Zohar, J | 5 |
| Chrysikakou, S | 1 |
| Giannou, H | 1 |
| Biba, A | 1 |
| Pallidi, S | 1 |
| Christodoulou, A | 1 |
| Maillis, A | 1 |
| Rabavilas, A | 1 |
| Gráf, M | 1 |
| Korff, S | 1 |
| Stein, DJ | 6 |
| Harvey, BH | 1 |
| Goodman, WK | 4 |
| McDougle, CJ | 2 |
| Price, LH | 4 |
| Barr, LC | 3 |
| Hills, OF | 1 |
| Caplik, JF | 1 |
| Charney, DS | 3 |
| Heninger, GR | 2 |
| Hadigan, CM | 1 |
| Walsh, BT | 1 |
| Buttinger, C | 1 |
| Hollander, E | 12 |
| Cohen, LJ | 2 |
| DeCaria, C | 6 |
| Saoud, JB | 3 |
| Cooper, TB | 2 |
| Islam, NN | 1 |
| Liebowitz, MR | 6 |
| Klein, DF | 4 |
| DeCaria, CM | 2 |
| Prohovnik, I | 1 |
| Simeon, D | 2 |
| Islam, N | 1 |
| Hwang, M | 1 |
| Wong, CM | 1 |
| Grossman, R | 1 |
| Cohen, L | 2 |
| Rosen, J | 1 |
| Broocks, A | 1 |
| Pigott, TA | 3 |
| Hill, JL | 5 |
| Canter, S | 1 |
| Grady, TA | 1 |
| L'Heureux, F | 2 |
| Murphy, DL | 6 |
| Kwon, J | 1 |
| Weiller, F | 1 |
| Liebowitz, M | 1 |
| Ho Pian, KL | 1 |
| den Boer, JA | 1 |
| de Bruin, WI | 1 |
| van Rijk, PP | 1 |
| Baumgarten, HG | 1 |
| Grozdanovic, Z | 1 |
| Khanna, S | 1 |
| John, JP | 1 |
| Reddy, LP | 1 |
| Erzegovesi, S | 1 |
| Martucci, L | 1 |
| Henin, M | 1 |
| Bellodi, L | 1 |
| Rubenstein, CS | 1 |
| Bernstein, SE | 2 |
| Nitescu, A | 2 |
| Gully, R | 2 |
| Suckow, RF | 2 |
| Gorman, JM | 3 |
| Grover, GN | 1 |
| Zohar-Kadouch, RC | 3 |
| Bihari, K | 1 |
| Pato, MT | 1 |
| Winslow, JT | 1 |
| Insel, TR | 4 |
| Fay, M | 1 |
| Cohen, B | 1 |
| Campeas, R | 2 |
| Papp, L | 1 |
| Woods, SW | 1 |
| Rasmussen, SA | 1 |
| Mueller, EA | 1 |
4 reviews available for 1-(3-chlorophenyl)piperazine and Anankastic Personality
| Article | Year |
|---|---|
Meta-Chlorophenylpiperazine-Induced Behavioral Changes in Obsessive-Compulsive Disorder Research: A Systematic Review of Rodent Studies.
Topics: Animals; Male; Obsessive-Compulsive Disorder; Rats; Rats, Sprague-Dawley; Rats, Wistar; Rodentia; Se | 2022 |
Role of serotonin in obsessive-compulsive disorder.
Topics: Biogenic Monoamines; Fenfluramine; Humans; Neuropeptides; Obsessive-Compulsive Disorder; Piperazines | 1998 |
The serotonin hypothesis of obsessive compulsive disorder: implications of pharmacologic challenge studies.
Topics: Biomarkers; Clomipramine; Humans; Neurotransmitter Uptake Inhibitors; Obsessive-Compulsive Disorder; | 1992 |
Neurobiology of obsessive compulsive disorder: a possible role for serotonin.
Topics: Humans; Obsessive-Compulsive Disorder; Piperazines; Receptors, Serotonin; Serotonin | 1990 |
22 trials available for 1-(3-chlorophenyl)piperazine and Anankastic Personality
| Article | Year |
|---|---|
Hypersensitivity of 5-HT2 receptors in OCD patients. An increased prolactin response after a challenge with meta-chlorophenylpiperazine and pre-treatment with ritanserin and placebo.
Topics: Adult; Dose-Response Relationship, Drug; Female; Humans; Hydrocortisone; Male; Middle Aged; Obsessiv | 2008 |
Serotonergic dissection of obsessive compulsive symptoms: a challenge study with m-chlorophenylpiperazine and sumatriptan.
Topics: Adult; Female; Humans; Hydrocortisone; Male; Middle Aged; Obsessive-Compulsive Disorder; Piperazines | 2004 |
m-Chlorophenylpiperazine in patients with obsessive-compulsive disorder: absence of symptom exacerbation.
Topics: Administration, Oral; Adolescent; Adult; Affect; Anxiety; Arousal; Double-Blind Method; Female; Huma | 1995 |
Behavioral and neuroendocrine responses to metaCPP in anorexia nervosa.
Topics: Adult; Affect; Anorexia Nervosa; Arousal; Body Mass Index; Body Weight; Double-Blind Method; Female; | 1995 |
A pilot study of biological predictors of treatment outcome in obsessive-compulsive disorder.
Topics: Adolescent; Adult; Ambulatory Care; Clomipramine; Dose-Response Relationship, Drug; Double-Blind Met | 1993 |
Induction of depersonalization by the serotonin agonist meta-chlorophenylpiperazine.
Topics: Adult; Animals; Arousal; Borderline Personality Disorder; Brain; Depersonalization; Double-Blind Met | 1995 |
Headache response to m-chlorophenylpiperazine in obsessive-compulsive disorder and normal controls.
Topics: Adolescent; Adult; Female; Headache; Humans; Male; Middle Aged; Obsessive-Compulsive Disorder; Piper | 1996 |
Seasonal effects in prolactin response to m-chlorophenylpiperazine challenge in obsessive-compulsive disorder.
Topics: Adolescent; Adult; Aged; Female; Humans; Male; Middle Aged; Obsessive-Compulsive Disorder; Photoperi | 1996 |
Acute intravenous administration of ondansetron and m-CPP, alone and in combination, in patients with obsessive-compulsive disorder (OCD): behavioral and biological results.
Topics: Adult; Analysis of Variance; Behavioral Symptoms; Double-Blind Method; Drug Interactions; Female; Hu | 1998 |
Serotonergic function in social phobia: comparison to normal control and obsessive-compulsive disorder subjects.
Topics: Adult; Analysis of Variance; Anxiety; Case-Control Studies; Female; Humans; Hydrocortisone; Male; Ne | 1998 |
Effects of meta-chlorophenylpiperazine on cerebral blood flow in obsessive-compulsive disorder and controls.
Topics: Adult; Cerebrovascular Circulation; Double-Blind Method; Female; Humans; Male; Obsessive-Compulsive | 1998 |
Neuroendocrine and behavioral responses to mCPP in Obsessive-Compulsive Disorder.
Topics: Administration, Oral; Adult; Arousal; Double-Blind Method; Female; Humans; Hydrocortisone; Hypothala | 2001 |
Low versus standard dose mCPP challenge in obsessive-compulsive patients.
Topics: Adult; Affect; Anxiety; Behavior; Cross-Over Studies; Disease Progression; Dose-Response Relationshi | 2001 |
A double-blind, placebo controlled study of trazodone in patients with obsessive-compulsive disorder.
Topics: Adolescent; Adult; Blood Platelets; Double-Blind Method; Female; Humans; Male; Middle Aged; Obsessiv | 1992 |
Serotonergic function in obsessive-compulsive disorder. Behavioral and neuroendocrine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers.
Topics: Administration, Oral; Adolescent; Adult; Double-Blind Method; Down-Regulation; Female; Fenfluramine; | 1992 |
Effects of chronic fluoxetine treatment on behavioral and neuroendocrine responses to meta-chlorophenylpiperazine in obsessive-compulsive disorder.
Topics: Adult; Arousal; Brain; Female; Fluoxetine; Humans; Hydrocortisone; Male; Obsessive-Compulsive Disord | 1991 |
Metergoline blocks the behavioral and neuroendocrine effects of orally administered m-chlorophenylpiperazine in patients with obsessive-compulsive disorder.
Topics: Administration, Oral; Adult; Double-Blind Method; Drug Interactions; Female; Humans; Hydrocortisone; | 1991 |
Serotonergic and noradrenergic sensitivity in obsessive-compulsive disorder: behavioral findings.
Topics: Adult; Clonidine; Fenfluramine; Humans; Male; Middle Aged; Obsessive-Compulsive Disorder; Piperazine | 1988 |
Obsessive-compulsive disorder: psychobiological approaches to diagnosis, treatment, and pathophysiology.
Topics: Adult; Brain; Clomipramine; Depressive Disorder; Desipramine; Diagnosis, Differential; Female; Human | 1987 |
More on self mutilation and obsessive compulsive disorder.
Topics: Adult; Clinical Trials as Topic; Double-Blind Method; Fluoxetine; Humans; Male; Obsessive-Compulsive | 1988 |
Serotonergic responsivity in obsessive-compulsive disorder. Effects of chronic clomipramine treatment.
Topics: Adult; Aged; Brain Chemistry; Clinical Trials as Topic; Clomipramine; Double-Blind Method; Female; H | 1988 |
Serotonergic responsivity in obsessive-compulsive disorder. Comparison of patients and healthy controls.
Topics: Adult; Affect; Aged; Behavior; Body Temperature; Female; Humans; Male; Metergoline; Middle Aged; Obs | 1987 |
15 other studies available for 1-(3-chlorophenyl)piperazine and Anankastic Personality
| Article | Year |
|---|---|
Fear extinction in an obsessive-compulsive disorder animal model: Influence of sex and estrous cycle.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Estrous Cycle; Extinction, Psycho | 2018 |
Effects of agomelatine in a murine model of obsessive-compulsive disorder: interaction with meta-chlorophenylpiperazine, bicuculline, and diazepam.
Topics: Acetamides; Animals; Antidepressive Agents; Behavior, Animal; Bicuculline; Diazepam; Disease Models, | 2013 |
Separate mechanisms for development and performance of compulsive checking in the quinpirole sensitization rat model of obsessive-compulsive disorder (OCD).
Topics: Animals; Compulsive Behavior; Disease Models, Animal; Male; Obsessive-Compulsive Disorder; Piperazin | 2014 |
5-HT2A/C receptors do not mediate the attenuation of compulsive checking by mCPP in the quinpirole sensitization rat model of obsessive-compulsive disorder (OCD).
Topics: Animals; Compulsive Behavior; Disease Models, Animal; Male; Obsessive-Compulsive Disorder; Piperazin | 2015 |
Dopaminergic and serotonergic modulation of persistent behaviour in the reinforced spatial alternation model of obsessive-compulsive disorder.
Topics: Animals; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Fluoxetine; Ma | 2008 |
Ritualistic chewing behavior induced by mCPP in the rat is an animal model of obsessive compulsive disorder.
Topics: Animals; Behavior, Animal; Clomipramine; Diazepam; Disease Models, Animal; Dopamine Antagonists; Flu | 2013 |
Effects of the serotonergic agonist mCPP on male rats in the quinpirole sensitization model of obsessive-compulsive disorder (OCD).
Topics: Animals; Behavior, Animal; Compulsive Behavior; Disease Models, Animal; Dose-Response Relationship, | 2013 |
Reinforced spatial alternation as an animal model of obsessive-compulsive disorder (OCD): investigation of 5-HT2C and 5-HT1D receptor involvement in OCD pathophysiology.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Desipramine; Diazepam; Disease Model | 2005 |
5-HT2c receptor activation induces grooming behaviour in rats: possible correlations with obsessive-compulsive disorder.
Topics: Aminopyridines; Animals; Grooming; Indoles; Male; Obsessive-Compulsive Disorder; Piperazines; Quinol | 2006 |
Stereotypic behaviour in the deer mouse: pharmacological validation and relevance for obsessive compulsive disorder.
Topics: Animals; Antidepressive Agents, Tricyclic; Behavior, Animal; Desipramine; Disease Models, Animal; Do | 2008 |
The serotonin hypothesis of obsessive compulsive disorder.
Topics: Animals; Arousal; Brain; Humans; Hydrocortisone; Obsessive-Compulsive Disorder; Piperazines; Prolact | 1993 |
Timing of neuroendocrine responses and effect of m-CPP and fenfluramine plasma levels in OCD.
Topics: Adult; Female; Fenfluramine; Humans; Hydrocortisone; Male; Obsessive-Compulsive Disorder; Piperazine | 1993 |
Increased cerebral blood flow during m-CPP exacerbation of obsessive-compulsive disorder.
Topics: Administration, Oral; Adult; Aged; Cerebral Cortex; Female; Humans; Image Processing, Computer-Assis | 1995 |
Neurologic soft signs in obsessive-compulsive disorder.
Topics: Adult; Anxiety Disorders; Central Nervous System Diseases; Clomipramine; Clonidine; Depressive Disor | 1991 |
Serotonin function in obsessive-compulsive disorder. A comparison of the effects of tryptophan and m-chlorophenylpiperazine in patients and healthy subjects.
Topics: Adult; Female; Growth Hormone; Humans; Hydrocortisone; Male; Obsessive-Compulsive Disorder; Personal | 1988 |